SAYER KEVIN R 4

What Happened
Kevin R. Sayer, Executive Chair and Director of Dexcom (DXCM), sold 26,759 shares in an open-market disposition on May 21, 2026 at $72.00 per share, totaling $1,926,648. The sale was reported on Form 4 filed May 26, 2026 and was executed pursuant to a previously adopted 10b5-1 trading plan.

Key Details

• Transaction date and price: May 21, 2026 — 26,759 shares sold at $72.00 each.
• Total proceeds: $1,926,648.
• Sale type/code: S (sale) executed under a 10b5-1 plan (see footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Mr. Sayer adopted a 10b5-1 plan on Feb 18, 2026; the shares were sold pursuant to that plan.
  • F2: The filing notes 106,972 unvested restricted stock units included in ownership reporting (32,749 granted Mar 8, 2026 vesting through Mar 8, 2027; 56,993 granted Mar 8, 2025 vesting through Mar 8, 2028; 17,230 granted Mar 8, 2024 vesting through Mar 8, 2027).
• Timeliness: The Form 4 was filed five days after the trade (May 21 trade, May 26 filing), which is later than the standard two-business-day reporting window—late filing reduces near-term transparency.

Context
Sales executed under a 10b5-1 plan are generally preplanned and are often routine portfolio-management transactions; they typically carry less informational weight about an insider’s current view of the company than unsolicited, ad-hoc trades. This filing documents a routine disposition rather than an option exercise or grant.